Filing summary
Entity and period: The supplied filing is BioSig Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, not a filing for Streamex Corp. The filing reports annual results, not a standalone 2020 fourth quarter. BioSig is an early-commercialization medical technology company developing the PURE EP cardiac electrophysiology signal-processing system.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 |
| Research and development expense | $18.1 million | $9.7 million |
| General and administrative expense | $41.0 million | $24.8 million |
| Operating loss | $59.2 million | $34.6 million |
| Net loss attributable to common shareholders | $52.2 million | $34.1 million |
| Basic and diluted loss per share | $1.87 | $1.65 |
| Cash used in operating activities | $26.6 million | $15.5 million |
| Cash at year-end | $28.3 million | $12.1 million |
Margins are not meaningful because the company reported no revenue. R&D increased 86% and G&A increased 65%; management attributed the increases to development activity, compensation (including equity compensation), professional services, and consulting. Equity-based compensation was a significant noncash expense; the cash-flow statement adds back $25.2 million.
Year-end working capital was $24.2 million. Total liabilities were approximately $5.1 million, largely accounts payable, accrued expenses, and lease liabilities; the company reported no convertible debentures outstanding. Series C preferred stock had $105,000 stated value and carries redemption, dividend, and covenant provisions. Financing activities provided $42.8 million in 2020, including common-stock and subsidiary-stock sales and option and warrant exercises.
Changes, outlook, and material developments
- BioSig received FDA 510(k) clearance for PURE EP in 2018. By March 2021, it reported more than 575 procedures by over 38 electrophysiologists at eight U.S. sites. Early blinded signal analysis rated 29 of 34 PURE EP signals equivalent to or better than comparator signals; the filing describes this as preliminary evidence, not a completed clinical trial.
- Three units contracted for purchase by St. David’s Healthcare in December 2020 were sold in February 2021, which the company described as its first commercial sale. BioSig reported no 2020 revenue.
- Management estimated that year-end cash, together with subsequent financing, would fund operations for approximately 14 months; elsewhere the filing describes at least 12 months from the financial-statement issuance date. The company expects continued operating losses and negative operating cash flow and may need further capital. It had a $45 million at-the-market facility, with approximately $42.5 million available at year-end, and a $75 million shelf registration subsequently declared effective.
- BioSig plans further commercialization and development, including a Mayo Clinic AI research program announced in January 2021. It expected to pursue ISO 13485 certification and a CE Mark filing during 2021 or early 2022, subject to notified-body guidance; these are plans, not completed milestones.
- ViralClear halted its Phase 2 merimepodib COVID-19 trial in October 2020 after a safety review identified an imbalance in survival outcomes in a patient subgroup. BioSig said it did not intend to continue developing the drug and would consider licensing or sale; the subsidiary was to return to its prior focus on applications of signal-processing technology.
- Key risks include limited commercialization and clinical evidence, dependence on additional financing, competition, regulatory and reimbursement uncertainty, COVID-19 disruption, and reliance on collaborators and contract manufacturing. The filing reports $3.7 million in purchase commitments, some modifiable or cancellable.
- Aurigene filed suit in January 2021 claiming $1.53 million in milestone and service payments. BioSig disputes liability and intends to defend the claim. The filing also describes the Trek Therapeutics asset purchase as a related-party transaction involving an entity controlled by a director.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for BioSig Technologies, Inc. (NASDAQ: BSGM), not Streamex Corp.
- Review audited statements and notes for the large year-over-year increase in losses, equity compensation, and accrued R&D expenses.
- Assess the cash runway assumptions, subsequent ATM proceeds, remaining financing capacity, and potential dilution from shares, options, warrants, and preferred-stock terms.
- Track the status and outcomes of PURE EP clinical evaluation, commercial placements, and European certification; distinguish preliminary signal comparisons from demonstrated clinical outcomes.
- Monitor the Aurigene litigation, purchase commitments, and any residual costs or proceeds related to winding down merimepodib.
- The auditor issued an unmodified opinion on the financial statements but did not audit internal control effectiveness. Management reported controls effective at year-end and said a previously reported segregation-of-duties weakness was remediated.